Kenji Sakamoto

Dr. Kenji Sakamoto


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2019 in Circulation Journal
Verified
Journal Article
Closed access
PDF file
KKKazuo Kimura
Kazuo Kimura
TKTakeshi Kimura
Takeshi Kimura
MIMasaharu Ishihara
Masaharu Ishihara
YNYoshihisa Nakagawa
Yoshihisa Nakagawa
KNKoichi Nakao
Koichi Nakao
OGon behalf of the Japanese Circulation Society Joint Working Group
on behalf of the Japanese Circulation Society Joint Working Group
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

1 August 2015 in JACC
Verified
Journal Article
Closed access
KTKenichi Tsujita
Kenichi Tsujita
SSSeigo Sugiyama
Seigo Sugiyama
HSHitoshi Sumida
Hitoshi Sumida
HSHideki Shimomura
Hideki Shimomura
TYTakuro Yamashita
Takuro Yamashita
HOHisao Ogawa
Hisao Ogawa

1 January 2020 in Hypertension
Verified
Journal Article
Closed access
PDF file
SYSatoru Yamamura
Satoru Yamamura
YIYasuhiro Izumiya
Yasuhiro Izumiya
SASatoshi Araki
Satoshi Araki
TNTaishi Nakamura
Taishi Nakamura
YKYuichi Kimura
Yuichi Kimura
KTKenichi Tsujita
Kenichi Tsujita
Sirt (Sirtuin) 7, the most recently identified mammalian sirtuin, has been shown to contribute to appropriate wound healing processes after acute cardiovascular insult. However, its role in the development of cardiac remodeling after pressure overload is unclear. Cardiomyocyte-specific Sirt7-knockout and control mice were subjected to pressure overload induced by transverse aortic constriction. Cardiac hypertrophy and functions were then examined in these mice. Sirt7 protein expression was increased in myocardial tissue after pressure overload. Transverse aortic constriction-induced increases in heart weight/tibial length were significantly augmented in cardiomyocyte-specific Sirt7-knockout mice compared with those of control mice. Histological analysis showed that the cardiomyocyte cross-sectional area and fibrosis area were significantly larger in cardiomyocyte-specific Sirt7-deficient mice. Cardiac contractile functions were markedly decreased in cardiomyocyte-specific Sirt7-deficient mice. Mechanistically, we found that Sirt7 interacted directly with GATA4 and that the exacerbation of phenylephrine-induced cardiac hypertrophy by Sirt7 knockdown was decreased by GATA4 knockdown. Sirt7 deacetylated GATA4 in cardiomyocytes and regulated its transcriptional activity. Interestingly, we demonstrated that treatment with nicotinamide mononucleotide, a known key NAD + intermediate, ameliorated agonist-induced cardiac hypertrophies in a Sirt7-dependent manner in vitro. Sirt7 deficiency in cardiomyocytes promotes cardiomyocyte hypertrophy in response to pressure overload. Sirt7 exerts its antihypertrophic effect by interacting with and promoting deacetylation of GATA4.

4 July 2019 in American Journal of Hypertension
Verified
Journal Article
Closed access
PDF file
DSDaisuke Sueta
Daisuke Sueta
EYEiichiro Yamamoto
Eiichiro Yamamoto
TNTaiki Nishihara
Taiki Nishihara
TTTakanori Tokitsu
Takanori Tokitsu
KFKoichiro Fujisue
Koichiro Fujisue
KTKenichi Tsujita
Kenichi Tsujita
The H2FPEF score is recognized as a simple method to diagnose heart failure (HF) with preserved left ventricular ejection fraction (HFpEF). We investigated the value of the H2FPEF score in predicting subsequent cardiovascular events in HFpEF patients. This study was a retrospective, single-center, observational study. We calculated the H2FPEF scores for 404 consecutive HFpEF patients. Subjects were subdivided into low- (0–3), intermediate- (4–6), and high-score (7–9) groups and followed for 50-months. The primary and secondary endpoints were composite cardiovascular/ cerebrovascular events (cardiovascular death, non-fatal myocardial infarction, unstable angina pectoris, hospitalization for HF decompensation and non-fatal stroke) occurrence and HF-related events (hospitalization for HF decompensation) occurrence at 50-months, respectively. Kaplan–Meier analyses demonstrated a significantly higher incidence of cardiovascular/cerebrovascular events among those with a higher H2FPEF score (log-rank test, P=0.005). The HF-related event rate was higher in proportion to the H2FPEF score (log-rank test, P<0.001). Multivariate Cox hazard analyses identified the H2FPEF score (per 1 point) as an independent predictor of cardiovascular and HF-related events (hazard ratio, 1.179; 95% confidence interval, 1.066-1.305; P=0.001 and hazard ratio, 1.288; 95% confidence interval, 1.134–1.463; P=0.001, respectively). Receiver operating characteristic analysis showed that the H2FPEF significantly predicted cardiovascular events (AUC 0.626, 95% CI 0.557–0.693; P<0.001) and HF-related events (AUC 0.680, 95%CI 0.600-0.759; P<0.001). The cutoff H2FPEF score was 5.5 for the identification of cardiovascular and HF-related events. The H2FPEF score might be a potentially useful marker for the prediction of cardiovascular and HF-related events in HFpEF patients.

1 December 2017 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Open access
PDF file
NTNoriaki Tabata
Noriaki Tabata
DSDaisuke Sueta
Daisuke Sueta
EYEiichiro Yamamoto
Eiichiro Yamamoto
STSeiji Takashio
Seiji Takashio
YAYuichiro Arima
Yuichiro Arima
HOHisao Ogawa
Hisao Ogawa
With the advancement in successfully treating different types of cancers, there is an immediate and increased need to focus on the risk and complexity of treating cardiovascular events in cancer survivors. This has led to the emergence of onco-cardiology/cardio-oncology field. We examined the varying incidence of cardiovascular events after percutaneous coronary intervention (PCI) in patients with or without cancer. Participants were divided into a non-malignant group and a malignant group, consisting of patients who were receiving or had ever received cancer treatment. The primary endpoint was target lesion revascularization (TLR) within 1 year of PCI. In the patient groups studied, we showed that the malignant group had a significantly higher probability of TLR than the non-malignant group (P = 0.002). Moreover, proportional hazards analyses identified malignancy as an independent predictor of TLR [hazard ratio (HR) 2.28, 95% confidential interval (CI) 1.3–4.0; P = 0.004]. Combining malignancy status with high-sensitivity C-reactive protein levels further increased the HR for TLR (HR 3.01, 95% CI 1.57–5.76; P = 0.001), and the net reclassification improvement was significant (15.2%, 95% CI 4.3–26%; P = 0.02). Time since completion of cancer treatment had an impact on the rate of TLR, with those patients with a current or recent cancer history having more TLR events within 1 year. We demonstrated a significant association between the recent history of cancer and the risk of recurrent coronary atherosclerosis in patients undergoing PCI and showed that malignancy status can predict the likelihood of cardiovascular events following this procedure.

6 May 2016 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
MIMasanobu Ishii
Masanobu Ishii
KKKoichi Kaikita
Koichi Kaikita
KSKoji Sato
Koji Sato
KYKenshi Yamanaga
Kenshi Yamanaga
TMTakashi Miyazaki
Takashi Miyazaki
HOHisao Ogawa
Hisao Ogawa
Background: Statin therapy reduces the risk of cardiovascular events in patients with obstructive coronary artery disease. The aim of the present study was to determine the effects of statins on the prognosis of patients with coronary vasospastic angina ( VSA ) free of significant atherosclerotic stenosis. Methods and Results: After exclusion of 475 from 1877 consecutive patients who underwent an acetylcholine‐provocation test between January 1991 and December 2010, data of 640 VSA patients without significant organic stenosis of the remaining 1402 were analyzed retrospectively. Propensity score matching was performed to reduce the effect of treatment‐selection bias and possible confounders. The primary endpoint was major adverse cardiac events ( MACE ), including cardiac death, nonfatal myocardial infarction, and unstable angina. Among the study population, dyslipidemia on admission was identified in 160 of 168 (95.2%) patients of the statin group compared with only 125 of 472 (26.5%) of the no‐statin group. Of the 640 patients, 24 (3.8%) developed MACE . Multivariate Cox hazard regression analysis identified statin therapy as a significant negative predictor of MACE (hazard ratio, 0.11; 95% CI, 0.02–0.84; P =0.033). In the propensity‐score matched cohorts (n=128 each), Kaplan–Meier survival curve showed a better 5‐year MACE ‐free survival rate for patients of the statin group compared to the no‐statin group (100% vs 91.7%, respectively; P =0.002). Conclusions: Statin therapy correlated with a lower rate of cardiovascular events in VSA patients free of significant organic stenosis. Statins seems to improve the prognosis of VSA patients free of significant organic stenosis.